Christopher Hubbard

On December 9, 2022, the Court of Appeal issued a decision applying the Van Breda framework and confirming that the presumptive connecting factors set out in Van Breda apply equally to contractual claims. The decision considered jurisdiction simpliciter and forum non conveniens, particularly in the context of contractual claims with international elements giving rise to questions of comity and universal jurisdiction.

Comprehensive genomic profiling of patients with advanced-stage cancer is becoming increasingly common, fueled by rapid advances in next-generation sequencing (NGS) technologies.1 At the same time, an increasing number of biomarker-directed therapies are becoming available, through both new US Food and Drug Administration (FDA) approvals and investigational clinical trials.

Abstract Comprehensive genomic profiling to inform targeted therapy selection is a central part of oncology care. However, the volume and complexity of alterations uncovered through genomic profiling make it difficult for oncologists to choose the most appropriate therapy for their patients. Here, we present a solution to this problem, The Molecular Registry of Tumors (MRT) and our Molecular Tumor Board (MTB).